Cyndeo Wealth Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Cyndeo Wealth Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.72M	Hold	118,444	–	–	0.18%	129
2026 Q1	$2.93M	Hold	118,444	–	–	0.15%	142
2025 Q4	$2.76M	Hold	118,444	–	–	0.15%	137
2025 Q3	$2.33M	Hold	118,444	–	–	0.13%	153
2025 Q2	$2.57M	Hold	118,444	–	–	0.15%	148
2025 Q1	$2.87M	Hold	118,444	–	–	0.19%	132
2024 Q4	$2.47M	Hold	118,444	–	–	0.17%	144
2024 Q3	$2.35M	Hold	118,444	–	–	0.16%	149
2024 Q2	$1.83M	Hold	118,444	–	–	0.14%	165
2024 Q1	$1.89M	Buy	118,444 +18,444	+18%	+$278K	0.16%	157
2023 Q4	$1.68M	Hold	100,000	–	–	0.16%	155
2023 Q3	$1.17M	Hold	100,000	–	–	0.12%	163
2023 Q2	$1.34M	Hold	100,000	–	–	0.14%	152
2023 Q1	$1.66M	Hold	100,000	–	–	0.18%	141
2022 Q4	$1.86M	Buy	+100,000	New	+$1.54M	0.22%	129

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cyndeo Wealth Partners's CPRX Position: Q2 2026 in Review

Cyndeo Wealth Partners held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 118,444 shares worth $3.72M. The position accounts for 0.18% of the portfolio, ranked #129.

Cyndeo Wealth Partners first reported a position in CPRX in Q4 2022 and has held it in 15 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Cyndeo Wealth Partners held 118,444 shares of Catalyst Pharmaceutical worth $3.72M as of Q2 2026.
Cyndeo Wealth Partners left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up 0.18% of Cyndeo Wealth Partners's portfolio in Q2 2026, its #129 holding.
Cyndeo Wealth Partners first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Cyndeo Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.